Calcium Fructoborate Prevents Skin Cancer Development in Balb-c Mice: Next Part, Reverse Inflammation, and Metabolic Alteration

dc.contributor.authorKisacam, Mehmet Ali
dc.contributor.authorKocamuftuoglu, Gonca Ozan
dc.contributor.authorOzan, Ibrahim Enver
dc.contributor.authorYaman, Mehmet
dc.contributor.authorOzan, SemaTemizer
dc.date.accessioned2026-08-12T17:35:34Z
dc.date.issued2021
dc.departmentFırat Üniversitesi
dc.description.abstractMetabolic alterations and inflammation are regarded as hallmarks of cancer. Glycolytic flux and intermediate accumulation lead to the production of building blocks and NADPH which is important in protecting the cell from oxidative damage. Inflammation causes the release of mediators responsible for regulating molecular mechanism affecting metabolic pathways. CaFB due to its cis-diol-rich feature may have the potential to interact with molecules taking part in cancer development. This study was aimed to investigate the effects of CaFB on metabolic alterations and inflammation in 7,12-dimethylbenz(a)anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate (TPA)-induced skin cancer. For this purpose, 92 Balb-c mice were distributed into 6 groups as control, CaFB, DMBA/TPA (D-T), treatment 1 (T1), 2 (T2), and 3(T3). Apart from control and CaFB in other groups, tumors initiated with 97.5-nmol DMBA and 6.5-nmol TPA. Treatment groups received 3 mg/kg/day CaFB with DMBA (T1), with TPA (T2), and after tumor formation (T3). In the D-T group, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity, 6-phosphogluconate dehydrogenase (PGD), glutathione (GSH), interleukin 6 (IL-6), (IL-1 beta), tumor necrosis factor-alpha (TNF-alpha) levels increased (p < 0.001) while malondialdehyde (MDA) levels decreased (p < 0.001) compared with that in control. CaFB application ameliorated DMBA-TPA effect according to the distribution time. It is noteworthy to consider CaFB as a potential preventive agent in skin cancer development.
dc.description.sponsorshipNational Boron Institution of Turkey [2016-31-07-15-003]
dc.description.sponsorshipThis project was funded by the National Boron Institution of Turkey grant number: 2016-31-07-15-003.
dc.identifier.doi10.1007/s12011-020-02363-w
dc.identifier.endpage2634
dc.identifier.issn0163-4984
dc.identifier.issn1559-0720
dc.identifier.issue7
dc.identifier.orcid0000-0002-3008-2671
dc.identifier.orcid0000-0003-0521-9434
dc.identifier.pmid32880800
dc.identifier.scopus2-s2.0-85090191309
dc.identifier.scopusqualityQ1
dc.identifier.startpage2627
dc.identifier.urihttps://doi.org/10.1007/s12011-020-02363-w
dc.identifier.urihttps://hdl.handle.net/11508/57600
dc.identifier.volume199
dc.identifier.wosWOS:000566461700002
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringernature
dc.relation.ispartofBiological Trace Element Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectCalcium fructoborate
dc.subjectSkin cancer
dc.subjectGlyceraldehyde-3-phosphate dehydrogenase
dc.subject6-Phosphogluconate dehydrogenase
dc.subjectInflammation
dc.subjectOxidative stress
dc.titleCalcium Fructoborate Prevents Skin Cancer Development in Balb-c Mice: Next Part, Reverse Inflammation, and Metabolic Alteration
dc.typeArticle

Dosyalar